Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents mixed signals. While there are positive aspects such as increased revenue expectations from OpRegen, potential partnerships, and optimism in the cell therapy market, there are concerns about rising expenses and net loss, as well as lack of specific data insights from ongoing studies. The Q&A reveals cautious optimism but also highlights uncertainties, particularly in data availability and competitive positioning. These factors balance each other out, suggesting a neutral impact on stock price.
Key Financial Performance
Cash Position $53.4 million as of March 31, 2026, expected to support operations into Q2 of 2028.
Total Revenues $1.7 million, a net increase of $0.2 million year-over-year, primarily driven by collaboration revenue recognized under the new research collaboration agreement with Demant.
Operating Expenses $9.3 million, an increase of $1.3 million year-over-year, driven by increases in R&D expenses and personnel costs.
R&D Expenses $4.2 million, an increase of $1.1 million year-over-year, primarily driven by $0.3 million for OPC1 program, $0.2 million for ReSonance program, and $0.7 million for preclinical and other undisclosed programs.
G&A Expenses $5.1 million, an increase of $0.2 million year-over-year, primarily driven by personnel costs, partially offset by services provided by third parties.
Loss from Operations $7.6 million, an increase of $1.1 million year-over-year, compared to $6.5 million for the same period in 2025.
Other Income $2.8 million, an increase compared to $2.4 million for the same period in 2025, primarily driven by exchange rate fluctuations and no warrant-related financing transaction costs incurred.
Net Loss $4.8 million or $0.02 per share basic and $0.03 per share diluted, compared to a net loss of $4.1 million or $0.02 per share for both basic and diluted for the same period in 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of COR1: Lineage launched COR1, a new wholly-owned corneal endothelial cell transplant program.
ILT1 Manufacturing Initiative: Successfully met the first internal milestone for the ILT1 manufacturing initiative.
ReSonance Program: Progressed the ReSonance auditory neuronal cell transplant program, including successful completion of 3 engineering runs and preparation for GMP suite manufacturing.
OpRegen Program Expansion: Genentech opened 11 new clinical sites in late 2025, bringing the total to 17 unique locations for the ongoing study.
Partnership with Demant: Lineage partnered with William Demant Invest for the ReSonance program, securing up to $12 million in funding for preclinical development.
AlloSCOPE Manufacturing Platform: Expanded the AlloSCOPE platform, enabling scalable and cost-effective cell manufacturing.
Scientific Advisory Board Formation: Established a new Scientific Advisory Board with Dr. Joachim Fruebis as the founding member.
Focus on Manufacturing Process: Prioritized robust, scalable manufacturing processes before clinical trials to reduce risks and ensure commercial viability.
Pipeline Diversification: Expanded the pipeline to include programs like COR1 and ILT1, leveraging the AlloSCOPE platform for diverse cell-based therapies.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Manufacturing Risks: The company acknowledges that cell therapy manufacturing is complex and any changes to the process can impact product characteristics, including efficacy. Delayed investments in manufacturing capabilities could be fatal to programs, and rushing into clinical testing without robust processes creates significant risks.
Regulatory and Commercial Risks: The company highlights the importance of optimizing surgical delivery and manufacturing processes to increase the probability of regulatory and commercial success. Failure to meet these standards could hinder product approval and market entry.
Supply Chain and Scalability Challenges: The company faces challenges in scaling up production for therapies like islet cells for type 1 diabetes, which require billions of cells per patient. Current methods are inadequate for commercial viability, and solving this issue is critical for success.
Financial Risks: The company reported a net loss of $4.8 million for the quarter and relies on cash reserves and potential milestone payments to fund operations. Any delays in achieving milestones or securing partnerships could impact financial stability.
Competitive Pressures: The company acknowledges competition in the cell therapy space, particularly for OpRegen, where competitors are also advancing their RPE transplant programs. Falling behind in manufacturing or clinical advancements could reduce market share.
Clinical Development Risks: The company is conducting trials for multiple programs, including OPC1 and ReSonance. Any safety or efficacy issues in these trials could delay or derail development. Additionally, the success of new delivery devices and formulations remains unproven.
Resource Allocation Risks: The company is managing a broad pipeline of programs, which could strain resources and focus. Inefficient allocation of resources may impact the progress of key initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
OpRegen Program: The company remains confident in the potential for OpRegen to advance into a multicenter controlled trial. Genentech has expanded the ongoing study to 17 unique locations, and the company believes the work being done will improve the product's profile and increase its probability of regulatory and commercial success. The company is bullish on OpRegen's potential to capture a significant portion of the multibillion-dollar GA market.
OPC1 Program: The company plans to present a supporting data package to the FDA later this year to introduce new cells into the ongoing DOSED trial. A larger comparative study of OPC1 is expected to be conducted either alone or with a partner. The ongoing study has been expanded to a second site, and updates on the first chronic SCI participant's 1-year follow-up visit are expected in the next earnings call.
ReSonance Program: The company has successfully completed three engineering runs and is preparing for GMP suite manufacturing. Functional animal testing is planned, and the company aims to complete GMP material manufacturing before discussing human testing with regulators. The program is fully funded for preclinical development leading to an IND filing.
COR1 Program: The company plans to advance the COR1 program into translational models and initial human testing. A timeline for the initiation of a clinical trial is expected to be provided in the next quarterly call.
ILT1 Manufacturing Initiative: The company is focused on scaling up undifferentiated pluripotent cells to support islet cell differentiation. If successful at larger scales, the company plans to demonstrate scalability with hypoimmune or non-hypoimmune cell lines. Progress updates on scale-up efforts are expected in the future.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What data supports OpRegen being characterized as disease-modifying?
A:The CEO mentioned that they do not have access to the data from the ongoing GAlette study but highlighted the opening of 11 sites (up from 6) as a positive indicator. He also noted that the recent Foundation Fighting Blindness (FFB) presentation included language about potentially modifying disease, which was absent in earlier CTS data. This change in language is seen as intentional and positive.
Q:What insights are available regarding photoreceptor recovery and bleb coverage in the GAlette trial?
A:The insights come entirely from their own Phase I/IIa data and publicly available data from other companies. They do not have specific insights from the ongoing GAlette study and cannot share any such data even if they had access.
Q:What is the status and next steps for the corneal endothelial cell program (COR1)?
A:The program is focused on developing a high-quality, reproducible manufacturing process. The CEO emphasized the importance of scalability, narrow specifications, and potency assays. The goal is to create an off-the-shelf, cryopreserved product that avoids reliance on cadaver-sourced cells.
Q:What are the updates on the ReSonance program and its $12 million funding?
A:The program has completed engineering runs, which is a gateway to GMP runs and FDA interactions. There is an annual go/no-go decision for the program, and the CEO is optimistic about its continuation. The $12 million funding is split roughly 2/3 for Lineage and 1/3 for Demant entities, covering third-party services.
Q:What are the CEO's thoughts on competitive data in the RPE cell and geographic atrophy space?
A:The CEO found Astellas' data update to be limited and not particularly threatening. He emphasized that Lineage remains in a leading position. Regarding complement inhibitors, he noted their small treatment effect and lack of evidence for improving visual function, contrasting this with the potential of RPE transplants to restore vision.
Q:What is the significance of Genentech's ARVO booth featuring OpRegen?
A:Genentech dedicated part of their ARVO booth to RPE transplants, which the CEO sees as a positive indicator of their commitment to the program and its potential impact.
Q:What is the status of the DOSED study for OPC1 and the CIRM grant application?
A:The DOSED study has treated its second patient, with chronic injuries being easier to enroll than subacute ones. The company reapplied for a CIRM grant in January, with a decision expected later in the summer. The program will continue regardless of the grant outcome.
Q:What are the challenges and risks in scaling up the ILT1 program?
A:The differentiation of pluripotent cells into islet cells is challenging, as islet cells do not expand well in culture. The company is taking a step-wise, risk-reducing approach to scale-up, focusing first on proof of concept at small scale and then moving to moderate scale.
Q:What is the novel model of deafening developed for the ReSonance program?
A:The model involves chemically inducing deafness to mimic disease conditions. This allows the company to test their auditory neuron cells in a relevant setting. The model is seen as an important milestone for advancing the program.
Q:What are the CEO's views on the competitive landscape for corneal endothelial cell therapy?
A:The CEO highlighted the limitations of cadaver-sourced cells, such as variability and supply constraints. He mentioned competitors like Aurion (now Alcon), Emmecell, and Cellusion, but emphasized the potential of Lineage's off-the-shelf, cryopreserved product to address these issues.
Q:Review of Unclear Management Responses
A:Management avoided providing specific insights into the ongoing GAlette study, citing lack of access to the data. They also did not provide a clear timeline for FDA interactions for the ReSonance program or specific details about the CIRM grant application outcome.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AlloSCOPE platform
CEnC
COR
Dr
ILT
Lineage
OPC
OpRegen
area
candidate
capability
cell bank
cell therapy
cell transplant
collaboration
delivery
differentiation
disease
increase
injury
islet cell
liter
manufacturing
material
opportunity
patient
period
problem
process development
product
production
program
scale
source
step
study
supply
testing
trial
vial
LCTX Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Unknown5-12
The earnings call presents mixed signals. While there are positive aspects such as increased revenue expectations from OpRegen, potential partnerships, and optimism in the cell therapy market, there are concerns about rising expenses and net loss, as well as lack of specific data insights from ongoing studies. The Q&A reveals cautious optimism but also highlights uncertainties, particularly in data availability and competitive positioning. These factors balance each other out, suggesting a neutral impact on stock price.
Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call indicates strong revenue growth, improved margins, and a significant reduction in net loss, showcasing operational efficiencies. The company's strategic initiatives in cell therapy, particularly the OpRegen program, along with optimistic market trends, signal positive future prospects. Despite the absence of shareholder return discussions, the financial health and strategic outlook suggest a positive sentiment. The lack of negative sentiment in the Q&A further supports a positive rating, with expectations of a stock price increase in the 2% to 8% range.
Lineage Cell Therapeutics, Inc. (LCTX) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call reveals mixed signals. Positives include potential $37 million milestone payment from OpRegen, new manufacturing processes, and strategic partnerships. However, the significant net loss, unclear management responses, and reliance on future funding present risks. The Q&A highlights potential expansion with the CIRM grant and partnership strategies, but uncertainties remain. Overall, the sentiment is balanced, leading to a neutral stock price prediction.
Lineage Cell Therapeutics, Inc. (LCTX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Prepared Remarks Transcript
Neutral9-13
LCTX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
